SCHEMBL4332806

SCHEMBL4332806

NC(=S)N(CC1CCCO1)N=Cc1ccc(-c2ccc(Cl)cc2)o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.44
PRMT5 O14744 1/20 0.43
WDR77 Q9BQA1 1/20 0.43
OXTR P30559 1/20 0.41
ALDH1A1 P00352 8/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
SMN1; SMN2 Q16637 6/20 0.40
MAPT P10636 5/20 0.39
KDM4E B2RXH2 4/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
HPGD P15428 5/20 0.38
NPSR1 Q6W5P4 3/20 0.38
ALOX12 P18054 2/20 0.38
LMNA P02545 1/20 0.38
PKM P14618 1/20 0.38
PSEN1 P49768 2/20 0.37
PSEN2 P49810 2/20 0.37
APH1B Q8WW43 2/20 0.37
NCSTN Q92542 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4328246 0.90 LMNA (0.46) POLBOXTRALDH1A1MEN1KMT2A
SCHEMBL4455897 0.90 KMT2A (0.50) POLBALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL4329481 0.89 KDM4E (0.44) POLBOXTRALDH1A1MEN1KMT2A
SCHEMBL4332906 0.77 PRMT5 (0.49) PRMT5WDR77ALDH1A1MEN1KMT2A
SCHEMBL4450066 0.76 PRMT5 (0.50) PRMT5WDR77ALDH1A1MEN1KMT2A
SCHEMBL4332803 0.75 GAA (0.61) POLBPRMT5WDR77ALDH1A1MEN1
SCHEMBL4332809 0.75 GAA (0.61) POLBPRMT5WDR77ALDH1A1MEN1
SCHEMBL4462859 0.73 PRMT5 (0.54) PRMT5WDR77ALDH1A1MEN1KMT2A
SCHEMBL4329107 0.71 ALDH1A1 (0.45) POLBPRMT5WDR77ALDH1A1MEN1
SCHEMBL4331963 0.70 PSEN1 (0.36) POLBOXTRALDH1A1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 POLB 3179/4885PRMT5 4357/4885WDR77 3480/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 POLB 3934/4885PRMT5 3764/4885WDR77 3201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.